Michael A. Egan

2.8k total citations
41 papers, 1.8k citations indexed

About

Michael A. Egan is a scholar working on Virology, Immunology and Infectious Diseases. According to data from OpenAlex, Michael A. Egan has authored 41 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Virology, 20 papers in Immunology and 15 papers in Infectious Diseases. Recurrent topics in Michael A. Egan's work include HIV Research and Treatment (24 papers), Immunotherapy and Immune Responses (12 papers) and Immune Cell Function and Interaction (10 papers). Michael A. Egan is often cited by papers focused on HIV Research and Treatment (24 papers), Immunotherapy and Immune Responses (12 papers) and Immune Cell Function and Interaction (10 papers). Michael A. Egan collaborates with scholars based in United States, Canada and Belgium. Michael A. Egan's co-authors include Robert F. Siliciano, John H. Eldridge, Zimra R. Israel, Shakuntala Megati, Marcelo J. Kuroda, Norman L. Letvin, Jörn E. Schmitz, Maninder K. Sidhu, George N. Pavlakis and Margherita Rosati and has published in prestigious journals such as Nature, PLoS ONE and Journal of Virology.

In The Last Decade

Michael A. Egan

40 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael A. Egan United States	25	883	850	608	559	510	41	1.8k
Amara Luckay United States	15	1.1k 1.3×	818 1.0×	611 1.0×	626 1.1×	315 0.6×	23	1.7k
Claude Méric France	21	561 0.6×	452 0.5×	582 1.0×	668 1.2×	514 1.0×	24	1.7k
Laura M. Walker United States	22	1.2k 1.3×	967 1.1×	1.0k 1.7×	553 1.0×	726 1.4×	41	2.5k
Mark L. Bagarazzi United States	20	621 0.7×	1.3k 1.6×	428 0.7×	585 1.0×	687 1.3×	38	2.0k
Kesen Dang United States	22	647 0.7×	1.6k 1.9×	535 0.9×	570 1.0×	807 1.6×	27	2.4k
M Francotte United States	13	660 0.7×	481 0.6×	370 0.6×	514 0.9×	440 0.9×	20	1.4k
J C Santoro United States	10	352 0.4×	787 0.9×	406 0.7×	439 0.8×	529 1.0×	12	1.5k
Lisa R. King United States	30	898 1.0×	1.3k 1.5×	683 1.1×	1.8k 3.2×	921 1.8×	59	3.1k
Tilahun Yilma United States	26	1.0k 1.2×	691 0.8×	589 1.0×	952 1.7×	416 0.8×	83	2.2k

Countries citing papers authored by Michael A. Egan

Since Specialization

Citations

This map shows the geographic impact of Michael A. Egan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael A. Egan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael A. Egan more than expected).

Fields of papers citing papers by Michael A. Egan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael A. Egan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael A. Egan. The network helps show where Michael A. Egan may publish in the future.

Co-authorship network of co-authors of Michael A. Egan

This figure shows the co-authorship network connecting the top 25 collaborators of Michael A. Egan. A scholar is included among the top collaborators of Michael A. Egan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael A. Egan. Michael A. Egan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Woolsey, Courtney, Robert W. Cross, Krystle N. Agans, et al.. (2022). A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge. PLoS neglected tropical diseases. 16(5). e0010433–e0010433. 31 indexed citations

Tsuji, Isamu, et al.. (2021). Development of a Novel Assay to Assess the Avidity of Dengue Virus-Specific Antibodies Elicited in Response to a Tetravalent Dengue Vaccine. The Journal of Infectious Diseases. 225(9). 1533–1544. 10 indexed citations

Clarke, David K., Rong Xu, Demetrius Matassov, et al.. (2020). Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial. The Lancet Infectious Diseases. 20(4). 455–466. 23 indexed citations

Elizaga, Marnie, Shuying S. Li, Nidhi Kochar, et al.. (2018). Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial. PLoS ONE. 13(9). e0202753–e0202753. 40 indexed citations

Matassov, Demetrius, Chad E. Mire, Theresa Latham, et al.. (2017). Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge. Journal of Virology. 92(3). 35 indexed citations

Matassov, Demetrius, Andrea Marzi, Rong Xu, et al.. (2015). Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus. The Journal of Infectious Diseases. 212(suppl 2). S443–S451. 39 indexed citations

Mpendo, Juliet, Gaudensia Mutua, Julien Nyombayire, et al.. (2015). A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults. PLoS ONE. 10(8). e0134287–e0134287. 28 indexed citations

Mire, Chad E., Demetrius Matassov, Joan B. Geisbert, et al.. (2015). Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. Nature. 520(7549). 688–691. 67 indexed citations

Hay, Christine M., Gregory J. Wilson, Marnie Elizaga, et al.. (2014). An HIV DNA Vaccine Delivered by Electroporation and Boosted by rVSV HIV-1 Gag Is Safe and Immunogenic in Healthy HIV-uninfected Adults. AIDS Research and Human Retroviruses. 30(S1). A17–A17. 1 indexed citations

10.

Megati, Shakuntala, Vidia Roopchand, Rong Xu, et al.. (2008). Modifying the HIV-1 env gp160 gene to improve pDNA vaccine-elicited cell-mediated immune responses. Vaccine. 26(40). 5083–5094. 14 indexed citations

11.

Chen, Tong, Rashed Abdullah, Amara Luckay, et al.. (2007). Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques. Vaccine. 25(41). 7132–7144. 24 indexed citations

12.

Egan, Michael A., Michele A. Kutzler, Shakuntala Megati, et al.. (2007). Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV89.6P challenge in rhesus macaques. Vaccine. 25(26). 4967–4982. 79 indexed citations

13.

Clarke, David K., David Cooper, Michael A. Egan, et al.. (2006). Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector. Springer Seminars in Immunopathology. 28(3). 239–253. 57 indexed citations

14.

Egan, Michael A., Siew Yen Chong, Shakuntala Megati, et al.. (2005). Priming with Plasmid DNAs Expressing Interleukin-12 and Simian Immunodeficiency Virus Gag Enhances the Immunogenicity and Efficacy of an Experimental AIDS Vaccine Based on Recombinant Vesicular Stomatitis Virus. AIDS Research and Human Retroviruses. 21(7). 629–643. 56 indexed citations

15.

Schadeck, Eva B., Maninder K. Sidhu, Michael A. Egan, et al.. (2005). A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine. 24(21). 4677–4687. 61 indexed citations

16.

Egan, Michael A., Shakuntala Megati, Vidia Roopchand, et al.. (2005). Rational design of a plasmid DNA vaccine capable of eliciting cell-mediated immune responses to multiple HIV antigens in mice. Vaccine. 24(21). 4510–4523. 25 indexed citations

17.

Egan, Michael A.. (2004). Current Prospects for the Development of a Therapeutic Vaccine for the Treatment of HIV Type 1 Infection. AIDS Research and Human Retroviruses. 20(8). 794–806. 13 indexed citations

18.

Egan, Michael A., Siew Yen Chong, Michael Hagen, et al.. (2004). A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques. Vaccine. 22(27-28). 3774–3788. 38 indexed citations

19.

Egan, Michael A., J. Tartaglia, Enzo Paoletti, et al.. (1995). Induction of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific Cytolytic T Lymphocyte Responses in Seronegative Adults by a Nonreplicating, Host-Range-Restricted Canarypox Vector (ALVAC) Carrying the HIV-1MN env Gene. The Journal of Infectious Diseases. 171(6). 1623–1627. 84 indexed citations

20.

Egan, Michael A., et al.. (1994). A Novel Method for Detection and ex Vivo Expansion of HIV Type 1-Specific Cytolytic T Lymphocytes. AIDS Research and Human Retroviruses. 10(11). 1427–1431. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact